Email  LinkedIn  Web

January 6, 2026



The Centers for Medicare & Medicaid Services (CMS) has begun formally notifying Medicare plans that they are expected to intensify monitoring of grievances and CTMs related to access‑to‑care issues at the pharmacy for the 10 drugs selected under the Medicare Drug Price Negotiation Program (MFP). CMS is emphasizing the need for heightened oversight on the member experience in accessing these drugs. Plans are being advised to take the following steps;


  • Report the number of grievances and CTMs, the CTM number, a summary of the access issue(s), and the root cause of the issue(s), (ex. repeated drug “out of stock’, non-enrollment of the delegated entity in the MTF DM, etc.).


  • Report this information to their CMS RO manager by the close of business on the last Friday of each month through the end of June 2026. 

 

Therefore, be sure your plan has the operational oversight in place to closely monitor grievances and CTMs to ensure any access‑to‑care complaints for the select drugs are quickly identified, categorized, and addressed. This can also include engaging PBMs for timely feedback on pharmacy‑level issues, including dispensing challenges, system edits, or other operational barriers that could affect beneficiary access. 

Website | About Us | Meet the Team | Solutions | Careers | Contact Us

BluePeak Advisors is a division of Gallagher Benefit Services, Inc.